“
TL;DR
This preclinical study used a mouse model to test the BET protein inhibitor JQ1 for peritoneal damage. The inhibitor reduced membrane thickening, inflammation, and oxidative stress by modulating key molecular pathways.
Antioxidants · 14 authors, 7 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This preclinical study used a mouse model to test the BET protein inhibitor JQ1 for peritoneal damage. The inhibitor reduced membrane thickening, inflammation, and oxidative stress by modulating key molecular pathways.
The study evaluated the BET protein inhibitor JQ1 in a mouse model of chlorhexidine gluconate (CHX)-induced peritoneal damage, with corroborating in vitro work on primary mesothelial cells from peritoneal dialysis patients and the MeT-5A cell line. In the mouse model, JQ1 treatment ameliorated peritoneal membrane thickening and inflammatory cell infiltration. It decreased gene overexpression of proinflammatory and profibrotic markers, inhibited NF-κB pathway activation, and restored NRF2/redox-controlled gene expression. Key limitations are that the primary evidence is preclinical (animal and cell line models), and the clinical relevance is indirect.